Navigation Links
GSK Update on FDA Review of Promacta(R) (Eltrombopag)
Date:6/20/2008

PHILADELPHIA, Pa. June 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura, as they require more time to review the application. The Prescription Drug User Fee action date has been extended to September 19, 2008.

On May 30, the Oncology Drugs Advisory Committee unanimously voted, 16-0, that eltrombopag demonstrated a favorable risk-benefit profile for the short-term treatment of patients with chronic idiopathic thrombocytopenic purpura, or ITP.

GSK will continue to work with the FDA towards the approval of eltrombopag in order to provide physicians and chronic ITP patients with a novel option for treating this difficult disease.

About Promacta(R) (Eltrombopag)

Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding. In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, common cold, and nausea.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

US Media inquiries: Jeff McLaughlin 1 919 483 2839

Mary Anne Rhyne 1 919 483 2839

Nancy Pekarek 1 215 751 7709

UK Media inquiries: Claire Brough 44 20 8047 5502

Philip Thomson 44 20 8047 5502

Alice Hunt 44 20 8047 5502

Gwenan White 44 20 8047 5502

US Analyst/Investor inquiries: Frank Murdolo 1 215 751 7002

Tom Curry 1 215 751 5419

UK Analyst/Investor inquiries: David Mawdsley 44 20 8047 5564

Sally Ferguson 44 20 8047 5543

Gary Davies 44 20 8047 5503


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. XTENT Announces European Regulatory Update
2. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Genmab Announces Updates on Phase III Cancer Studies
5. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
6. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
7. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
8. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
9. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
10. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
11. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/28/2017)... , July 28, 2017 EnvoyHealth, a Diplomat company, ... a program for CleverCap LITE, a technology designed to ... to deliver innovative health technology solutions and services that ... CleverCap LITE offers medication monitoring ... bottle cover: Records ...
(Date:7/27/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ... The Company reported second quarter net sales of $1.954 ... period, and an increase of 2.1% on a constant ... from the LDR Holding Corporation acquisition, second quarter 2017 ... or 0.3% on a constant currency basis. ...
Breaking Medicine Technology:
(Date:7/28/2017)... ... July 28, 2017 , ... ... of its budget on nutrition assistance programs. , Right now the most public ... . However, changes to other programs are under consideration, including WIC (Women, Infants, ...
(Date:7/28/2017)... ... July 28, 2017 , ... Kevin Harrington, one of the original Sharks from hit reality ... of a new DRTV campaign with My Real Earth. , Most people put their healthcare ... just as important as what we put in our bodies. After all, the skin is ...
(Date:7/28/2017)... OR (PRWEB) , ... July 28, 2017 , ... Date ... http://www.GlobalDragonTV.com , Like millions of first generation immigrants before her, Rose Hong ... beneficiary of generosity and sacrifice on the part of loving parents who made sure ...
(Date:7/28/2017)... ... 2017 , ... The DuPage County law firm of Mirabella Kincaid Frederick ... Ms. Cusack joins the team ready to provide clients with vigorous representation in ... in Peoria, Illinois, with a BA in Social Work. She earned her JD from ...
(Date:7/28/2017)... ... July 28, 2017 , ... As many parents, students, and teachers are getting ... sharpen mental acuity and address mental fatigue that can accompany long study hours, homework ... that can not only helps with school work but also in day-to-day functions on ...
Breaking Medicine News(10 mins):